報告摘要

Xerosis Treatment Market Research Report Information by Type (Medication [Antihistamines, Corticosteroids, Calcineurin Inhibitors, Anti-Inflammatory, Immunomodulators, and Others] and Personal Care Products), By Form (Tablets, Lotion, Cream, Cream, Ointment, Shower Forms, and Others), by Age Group (Paediatrics, Adults, and Elderly), By Gender (Male and Female), By Distribution Channel (Online and Offline) and by Region (North America, Europe, Asia-Pacific, South America, and Middle East and Africa) Forecast till 2032 Market Overview The Xerosis Treatment Market industry is anticipated to grow at a compound annual growth rate (CAGR) of 7.71% over the forecast period. The global market is expanding due to improved diagnostic capabilities, increased awareness, and innovative product formulations. The Xerosis Treatment Market is experiencing significant growth because of enhanced diagnosis and increased awareness. In recent years, there has been a substantial rise in public awareness of xerosis, a chronic skin condition that is distinguished by dried, rough, and flaky skin. A variety of factors, such as the increasing influence of digital media, pervasive educational campaigns, and active involvement from healthcare professionals, have contributed to this increase in awareness. Consequently, a greater number of individuals are identifying the symptoms of xerosis and requesting medical consultation to receive prompt treatment. The increased utilization of specialized remedies has been facilitated by the empowerment of patients to comprehend the significance of early diagnosis, which has been facilitated by improved access to information. As the condition is detected earlier, the treatment becomes more effective and efficient, resulting in a greater demand for both prescription-based and over-the-counter solutions. Market segment insights The Xerosis Treatment Market has been segmented into personal care products and medication based on type. Medication is further divided into antihistamines, corticosteroids, calcineurin inhibitors, anti-inflammatory, immunomodulators, and other drugs. The Market has been segmented into tablets, lotions, creams, ointments, lubricants, shower foams, and other products based on their form. Xerosis Treatment Market has been segmented into paediatrics, adults, and the elderly based on age. The market has been divided into online and offline segments based on the distribution channel. Regional Perspectives The market is segmented into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. The North American xerosis treatment market, which encompasses Canada and Mexico, is experiencing consistent growth because of the increasing demand for non-invasive treatments. The region's market growth is primarily driven by the rising prevalence of xerosis and other analogous conditions, such as eczema and psoriasis, in both the United States and Canada. The xerosis treatment market in Europe is experiencing development due to the rising prevalence of skin conditions, including psoriasis, eczema, and xerosis, particularly among older populations. The European market is experiencing an increase in demand for both topical and oral treatments, which is being driven by the increasing awareness of skin health and the availability of a diverse range of treatment alternative. The xerosis treatment market is expanding in the Asia-Pacific (APAC) region as a result of the increased prevalence of skin disorders, particularly in Japan, China, and India. Urbanization, altering climate patterns, and elevated pollution levels are all contributing factors to the increasing prevalence of xerosis and associated skin conditions. Furthermore, the demand for personal care and medical products is being stimulated by the growing awareness of health and hygiene. Primary Players Bayer AG (Germany), Reddy's Laboratories Ltd. (India), Johnson & Johnson Inc. (US), Galderma (Switzerland), Thornton & Ross Ltd. (UK), Amgen Inc. (US), Procter & Gamble (US), Unilever (UK), Pfizer Inc. (US), and Cipla (India) are among the key companies in the Xerosis Treatment Market.

目錄 Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ............................................................................................................... 21 2 MARKET INTRODUCTION ............................................................................................................ 23 2.1 DEFINITION .................................................................................................................................................................. 23 2.2 SCOPE OF THE STUDY .............................................................................................................................................. 23 2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 23 2.4 MARKET STRUCTURE .............................................................................................................................................. 23 3 RESEARCH METHODOLOGY ...................................................................................................... 24 3.1 OVERVIEW .................................................................................................................................................................... 24 3.2 DATA FLOW .................................................................................................................................................................. 26 3.2.1 DATA MINING PROCESS ................................................................................................................................. 26 3.3 PURCHASED DATABASE: ......................................................................................................................................... 27 3.4 SECONDARY SOURCES: ............................................................................................................................................ 28 3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................................. 29 3.5 PRIMARY RESEARCH: ............................................................................................................................................... 30 3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................................. 31 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 32 3.6.1 REVENUE ANALYSIS APPROACH ..................................................................................................................... 32 3.7 DATA FORECASTING................................................................................................................................................. 33 3.7.1 DATA FORECASTING TYPE .............................................................................................................................. 33 3.8 DATA MODELING ........................................................................................................................................................ 34 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................................................................................................ 34 3.8.2 DATA MODELING: ........................................................................................................................................... 35 3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 37 4 MARKET DYNAMICS .................................................................................................................... 39 4.1 INTRODUCTION ........................................................................................................................................................... 39 4.2 DRIVERS ......................................................................................................................................................................... 40 4.2.1 RISING AWARENESS AND IMPROVED DIAGNOSIS ............................................................................................ 40 4.2.2 INNOVATIVE PRODUCT FORMULATIONS ......................................................................................................... 40 4.2.3 RISE IN DISPOSABLE INCOME AND SPENDING ON SKINCARE ........................................................................... 41 4.3 RESTRAINTS ................................................................................................................................................................ 42 4.3.1 SIDE EFFECTS ASSOCIATED WITH THE XEROSIS TREATMENT DRUGS .............................................................. 42 4.4 OPPORTUNITY ............................................................................................................................................................. 43 4.4.1 GROWING GERIATRIC POPULATION ................................................................................................................ 43 4.4.2 INCREASE IN SELF-CARE PRACTICES FOR XEROSIS ......................................................................................... 44 4.4.3 ONGOING CLINICAL TRIALS AND UNIVERSITIES STUDIES ................................................................................. 44 MARKET FACTOR ANALYSIS ............................................................................................................ 45 4.5 PORTER'S FIVE FORCES MODEL ........................................................................................................................... 45 4.5.1 THREAT OF NEW ENTRANTS ........................................................................................................................... 45 4.5.2 BARGAINING POWER OF SUPPLIERS ............................................................................................................... 46 4.5.3 THREAT OF SUBSTITUTES .............................................................................................................................. 46 4.5.4 BARGAINING POWER OF BUYERS .................................................................................................................... 46 4.5.5 INTENSITY OF RIVALRY .................................................................................................................................. 46 4.6 IMPACT OF COVID-19 ON GLOBAL XEROSIS TREATMENT MARKET ...................................................... 47 4.7 EPIDEMIOLOGY ANALYSIS ..................................................................................................................................... 47 4.8 MARKET TRENDS ...................................................................................................................................................... 48 5 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE ................................................................. 51 5.1 OVERVIEW .................................................................................................................................................................... 51 5.2 MEDICATION ................................................................................................................................................................ 53 5.2.1 ANTIHISTAMINES ........................................................................................................................................... 54 5.2.2 CORTICOSTEROIDS ......................................................................................................................................... 55 5.2.3 CALCINEURIN INHIBITORS .............................................................................................................................. 55 5.2.4 ANTI-INFLAMMATORY .................................................................................................................................... 56 5.2.5 IMMUNOMODULATORS ................................................................................................................................... 56 5.2.6 OTHERS ......................................................................................................................................................... 57 5.3 PERSONAL CARE PRODUCTS ................................................................................................................................. 57 6 GLOBAL XEROSIS TREATMENT MARKET, BY FORM ............................................................... 58 6.1 OVERVIEW .................................................................................................................................................................... 58 6.2 TABLETS........................................................................................................................................................................ 61 6.3 LOTION ........................................................................................................................................................................... 61 6.4 CREAM ........................................................................................................................................................................... 62 6.5 OINTMENT .................................................................................................................................................................... 62 6.6 SHOWER FOAMS ........................................................................................................................................................ 63 6.7 OTHERS .......................................................................................................................................................................... 63 7 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP .................................................... 64 7.1 OVERVIEW .................................................................................................................................................................... 64 7.2 PAEDIATRICS ............................................................................................................................................................... 66 7.3 ADULTS .......................................................................................................................................................................... 67 7.4 ELDERLY ........................................................................................................................................................................ 67 8 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER ........................................................... 68 8.1 OVERVIEW .................................................................................................................................................................... 68 8.2 MALE .............................................................................................................................................................................. 70 8.3 FEMALE ......................................................................................................................................................................... 71 9 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL ............................... 72 9.1 OVERVIEW .................................................................................................................................................................... 72 9.2 ONLINE ........................................................................................................................................................................... 74 9.3 OFFLINE ......................................................................................................................................................................... 75 10 GLOBAL XEROSIS TREATMENT MARKET, BY REGION ............................................................ 76 10.1 OVERVIEW .................................................................................................................................................................... 76 10.2 NORTH AMERICA ....................................................................................................................................................... 77 10.2.1 US.................................................................................................................................................................. 81 10.2.2 CANADA ........................................................................................................................................................ 83 10.3 EUROPE .......................................................................................................................................................................... 85 10.3.1 GERMANY ...................................................................................................................................................... 89 10.3.2 FRANCE ......................................................................................................................................................... 91 10.3.3 UK ................................................................................................................................................................. 93 10.3.4 SPAIN ............................................................................................................................................................ 95 10.3.5 ITALY ............................................................................................................................................................. 97 10.3.6 RUSSIA .......................................................................................................................................................... 99 10.3.7 REST OF EUROPE ............................................................................................................................................ 101 10.4 ASIA PACIFIC ............................................................................................................................................................... 103 10.4.1 CHINA ............................................................................................................................................................ 107 10.4.2 INDIA ............................................................................................................................................................. 109 10.4.3 JAPAN ........................................................................................................................................................... 111 10.4.4 SOUTH KOREA ................................................................................................................................................ 113 10.4.5 MALAYSIA ..................................................................................................................................................... 116 10.4.6 THAILAND ...................................................................................................................................................... 118 10.4.7 INDONESIA ..................................................................................................................................................... 120 10.4.8 REST OF ASIA PACIFIC.................................................................................................................................... 122 10.5 SOUTH AMERICA ....................................................................................................................................................... 124 10.5.1 BRAZIL ........................................................................................................................................................... 128 10.5.2 MEXICO ......................................................................................................................................................... 130 10.5.3 ARGENTINA ................................................................................................................................................... 132 10.5.4 REST OF SOUTH AMERICA .............................................................................................................................. 134 10.6 MIDDLE EAST AND AFRICA .................................................................................................................................... 136 10.6.1 GCC COUNTRIES............................................................................................................................................. 140 10.6.2 SOUTH AFRICA ............................................................................................................................................... 142 10.6.3 REST OF MEA ................................................................................................................................................. 144 11 COMPETITIVE LANDSCAPE ........................................................................................................ 148 11.1 INTRODUCTION ........................................................................................................................................................... 148 11.2 MARKET SHARE ANALYSIS, 2023 ....................................................................................................................... 148 11.3 COMPETITOR DASHBOARD..................................................................................................................................... 149 11.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................................. 150 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL .............................................................................. 150 11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 151 11.1.1 PRODUCT LAUNCH ......................................................................................................................................... 151 12 COMPANY PROFILES .................................................................................................................. 152 12.1 AMGEN INC................................................................................................................................................................... 152 12.1.1 COMPANY OVERVIEW ..................................................................................................................................... 152 12.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 153 12.1.3 PRODUCTS OFFERED ...................................................................................................................................... 154 12.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 154 12.1.5 SWOT ANALYSIS ............................................................................................................................................ 154 12.1.6 KEY STRATEGIES ............................................................................................................................................ 155 12.2 PROCTER & GAMBLE ................................................................................................................................................. 156 12.2.1 COMPANY OVERVIEW ..................................................................................................................................... 156 12.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 157 12.2.3 PRODUCTS OFFERED ...................................................................................................................................... 158 12.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 158 12.2.5 SWOT ANALYSIS ............................................................................................................................................ 159 12.2.6 KEY STRATEGIES ............................................................................................................................................ 159 12.3 UNILEVER ..................................................................................................................................................................... 160 12.3.1 COMPANY OVERVIEW ..................................................................................................................................... 160 12.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 161 12.3.3 PRODUCTS OFFERED ...................................................................................................................................... 162 12.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 162 12.3.5 KEY STRATEGIES ............................................................................................................................................ 163 12.4 PFIZER INC. ................................................................................................................................................................... 164 12.4.1 COMPANY OVERVIEW ..................................................................................................................................... 164 12.4.2 FINANCIAL OVERVIEW .................................................................................................................................... 165 12.4.3 PRODUCTS OFFERED ...................................................................................................................................... 166 12.4.4 KEY DEVELOPMENTS ...................................................................................................................................... 166 12.4.5 SWOT ANALYSIS ............................................................................................................................................ 166 12.4.6 KEY STRATEGIES ............................................................................................................................................ 167 12.5 CIPLA .............................................................................................................................................................................. 168 12.5.1 COMPANY OVERVIEW ..................................................................................................................................... 168 12.5.2 FINANCIAL OVERVIEW .................................................................................................................................... 169 12.5.3 PRODUCTS OFFERED ...................................................................................................................................... 169 12.5.4 KEY DEVELOPMENTS ...................................................................................................................................... 169 12.5.5 KEY STRATEGIES ............................................................................................................................................ 170 12.6 BAYER AG ..................................................................................................................................................................... 170 12.6.1 COMPANY OVERVIEW ..................................................................................................................................... 170 12.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 172 12.6.3 PRODUCTS OFFERED ...................................................................................................................................... 172 12.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 173 12.6.5 SWOT ANALYSIS ............................................................................................................................................ 173 12.6.6 KEY STRATEGY ............................................................................................................................................... 173 12.7 JOHNSON & JOHNSON INC. ..................................................................................................................................... 175 12.7.1 COMPANY OVERVIEW ..................................................................................................................................... 175 12.7.2 FINANCIAL OVERVIEW .................................................................................................................................... 176 12.7.3 PRODUCTS OFFERED ...................................................................................................................................... 177 12.7.4 KEY DEVELOPMENTS ...................................................................................................................................... 177 12.7.5 SWOT ANALYSIS ............................................................................................................................................ 178 12.7.6 KEY STRATEGIES ............................................................................................................................................ 178 12.8 GALDERMA ................................................................................................................................................................... 179 12.8.1 COMPANY OVERVIEW ..................................................................................................................................... 179 12.8.2 FINANCIAL OVERVIEW .................................................................................................................................... 180 12.8.3 PRODUCT OFFERED ........................................................................................................................................ 180 12.8.4 KEY DEVELOPMENTS ...................................................................................................................................... 181 12.8.5 KEY STRATEGIES ............................................................................................................................................ 181 12.9 DR. REDDY’S LABORATORIES LTD. ....................................................................................................................... 182 12.9.1 COMPANY OVERVIEW ................................................................................................................................... 182 12.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 183 12.9.3 PRODUCT OFFERED ........................................................................................................................................ 183 12.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 184 12.9.5 KEY STRATEGIES ............................................................................................................................................ 184 12.10 THORNTON & ROSS LTD. .......................................................................................................................................... 185 12.10.1 COMPANY OVERVIEW ..................................................................................................................................... 185 12.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 185 12.10.3 PRODUCT OFFERED ........................................................................................................................................ 185 12.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 186 12.10.5 KEY STRATEGIES ............................................................................................................................................ 186 13 DATA CITATIONS ......................................................................................................................... 187

圖表清單 List of Tables & Figures

LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 35 TABLE 2 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 53 TABLE 3 GLOBAL XEROSIS TREATMENT MARKET, FOR MEDICATION, BY REGION, 2019–2032 (USD MILLION) 53 TABLE 4 GLOBAL XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 54 TABLE 5 GLOBAL XEROSIS TREATMENT MARKET, FOR ANTIHISTAMINES, BY REGION, 2019–2032 (USD MILLION) 54 TABLE 6 GLOBAL XEROSIS TREATMENT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2019–2032 (USD MILLION) 55 TABLE 7 GLOBAL XEROSIS TREATMENT MARKET, FOR CALCINEURIN INHIBITORS, BY REGION, 2019–2032 (USD MILLION) 55 TABLE 8 GLOBAL XEROSIS TREATMENT MARKET, FOR ANTI-INFLAMMATORY, BY REGION, 2019–2032 (USD MILLION) 56 TABLE 9 GLOBAL XEROSIS TREATMENT MARKET, FOR IMMUNOMODULATORS, BY REGION, 2019–2032 (USD MILLION) 56 TABLE 10 GLOBAL XEROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 57 TABLE 11 GLOBAL XEROSIS TREATMENT MARKET, FOR PERSONAL CARE PRODUCTS, BY REGION, 2019–2032 (USD MILLION) 57 TABLE 12 GLOBAL XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 60 TABLE 13 GLOBAL XEROSIS TREATMENT MARKET, FOR TABLETS, BY REGION, 2019–2032 (USD MILLION) 61 TABLE 14 GLOBAL XEROSIS TREATMENT MARKET, FOR LOTION, BY REGION, 2019–2032 (USD MILLION) 61 TABLE 15 GLOBAL XEROSIS TREATMENT MARKET, FOR CREAM, BY REGION, 2019–2032 (USD MILLION) 62 TABLE 16 GLOBAL XEROSIS TREATMENT MARKET, FOR OINTMENT, BY REGION, 2019–2032 (USD MILLION) 62 TABLE 17 GLOBAL XEROSIS TREATMENT MARKET, FOR SHOWER FOAMS, BY REGION, 2019–2032 (USD MILLION) 63 TABLE 18 GLOBAL XEROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 63 TABLE 19 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 66 TABLE 20 GLOBAL XEROSIS TREATMENT MARKET, FOR PAEDIATRICS, BY REGION, 2019–2032 (USD MILLION) 66 TABLE 21 GLOBAL XEROSIS TREATMENT MARKET, FOR ADULTS, BY REGION, 2019–2032 (USD MILLION) 67 TABLE 22 GLOBAL XEROSIS TREATMENT MARKET, FOR ELDERLY, BY REGION, 2019–2032 (USD MILLION) 67 TABLE 23 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 69 TABLE 24 GLOBAL XEROSIS TREATMENT MARKET, FOR MALE, BY REGION, 2019–2032 (USD MILLION) 70 TABLE 25 GLOBAL XEROSIS TREATMENT MARKET, FOR FEMALE, BY REGION, 2019–2032 (USD MILLION) 71 TABLE 26 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 74 TABLE 27 GLOBAL XEROSIS TREATMENT MARKET, FOR ONLINE, BY REGION, 2019–2032 (USD MILLION) 74 TABLE 28 GLOBAL XEROSIS TREATMENT MARKET, FOR OFFLINE, BY REGION, 2019–2032 (USD MILLION) 75 TABLE 29 GLOBAL XEROSIS TREATMENT MARKET, BY REGION, 2019–2032 (USD MILLION) 76 TABLE 30 NORTH AMERICA XEROSIS TREATMENT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 79 TABLE 31 NORTH AMERICA XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 79 TABLE 32 NORTH AMERICA XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 80 TABLE 33 NORTH AMERICA XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 80 TABLE 34 NORTH AMERICA XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 80 TABLE 35 NORTH AMERICA XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 81 TABLE 36 NORTH AMERICA XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 81 TABLE 37 US: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 81 TABLE 38 US: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 82 TABLE 39 US: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 82 TABLE 40 US: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 82 TABLE 41 US: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 83 TABLE 42 US: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 83 TABLE 43 CANADA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 83 TABLE 44 CANADA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 83 TABLE 45 CANADA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 84 TABLE 46 CANADA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 84 TABLE 47 CANADA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 85 TABLE 48 CANADA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 85 TABLE 49 EUROPE XEROSIS TREATMENT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 87 TABLE 50 EUROPE: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 87 TABLE 51 EUROPE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 88 TABLE 52 EUROPE: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 88 TABLE 53 EUROPE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 88 TABLE 54 EUROPE: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 89 TABLE 55 EUROPE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 89 TABLE 56 GERMANY: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 89 TABLE 57 GERMANY: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 90 TABLE 58 GERMANY: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 90 TABLE 59 GERMANY: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 90 TABLE 60 GERMANY: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 91 TABLE 61 GERMANY: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 91 TABLE 62 FRANCE: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 91 TABLE 63 FRANCE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 92 TABLE 64 FRANCE: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 92 TABLE 65 FRANCE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 92 TABLE 66 FRANCE: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 93 TABLE 67 FRANCE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 93 TABLE 68 UK: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 93 TABLE 69 UK: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 94 TABLE 70 FRANCE: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 94 TABLE 71 FRANCE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 94 TABLE 72 FRANCE: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 95 TABLE 73 FRANCE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 95 TABLE 74 SPAIN: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 95 TABLE 75 SPAIN: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 96 TABLE 76 SPAIN: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 96 TABLE 77 SPAIN: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 96 TABLE 78 SPAIN: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 97 TABLE 79 SPAIN: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 97 TABLE 80 ITALY: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 97 TABLE 81 ITALY: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 98 TABLE 82 ITALY: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 98 TABLE 83 ITALY: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 98 TABLE 84 ITALY: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 99 TABLE 85 ITALY: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 99 TABLE 86 RUSSIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 99 TABLE 87 RUSSIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 100 TABLE 88 RUSSIA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 100 TABLE 89 RUSSIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 100 TABLE 90 RUSSIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 101 TABLE 91 RUSSIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 101 TABLE 92 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 101 TABLE 93 REST OF EUROPE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 102 TABLE 94 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 102 TABLE 95 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 102 TABLE 96 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 103 TABLE 97 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 103 TABLE 98 ASIA PACIFIC XEROSIS TREATMENT MARKET, BY REGION, 2019–2032 (USD MILLION) 105 TABLE 99 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 105 TABLE 100 ASIA PACIFIC: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 106 TABLE 101 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 106 TABLE 102 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 106 TABLE 103 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 107 TABLE 104 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 107 TABLE 105 CHINA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 107 TABLE 106 CHINA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 108 TABLE 107 CHINA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 108 TABLE 108 CHINA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 108 TABLE 109 CHINA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 109 TABLE 110 CHINA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 109 TABLE 111 INDIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 109 TABLE 112 INDIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 110 TABLE 113 INDIA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 110 TABLE 114 INDIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 110 TABLE 115 INDIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 111 TABLE 116 INDIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 111 TABLE 117 JAPAN: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 111 TABLE 118 JAPAN: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 111 TABLE 119 JAPAN: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 112 TABLE 120 JAPAN: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 112 TABLE 121 JAPAN: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 113 TABLE 122 JAPAN: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 113 TABLE 123 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 113 TABLE 124 SOUTH KOREA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 114 TABLE 125 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 114 TABLE 126 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 115 TABLE 127 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 115 TABLE 128 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 115 TABLE 129 MALAYSIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 116 TABLE 130 MALAYSIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 116 TABLE 131 MALAYSIA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 116 TABLE 132 MALAYSIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 117 TABLE 133 MALAYSIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 117 TABLE 134 MALAYSIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 117 TABLE 135 THAILAND: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 118 TABLE 136 THAILAND: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 118 TABLE 137 THAILAND: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 118 TABLE 138 THAILAND: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 119 TABLE 139 THAILAND: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 119 TABLE 140 THAILAND: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 119 TABLE 141 INDONESIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 120 TABLE 142 INDONESIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 120 TABLE 143 INDONESIA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 120 TABLE 144 INDONESIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 121 TABLE 145 INDONESIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 121 TABLE 146 INDONESIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 121 TABLE 147 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 122 TABLE 148 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 122 TABLE 149 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 122 TABLE 150 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 123 TABLE 151 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 123 TABLE 152 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 123 TABLE 153 SOUTH AMERICA XEROSIS TREATMENT MARKET, BY REGION, 2019–2032 (USD MILLION) 125 TABLE 154 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 126 TABLE 155 SOUTH AMERICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 126 TABLE 156 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 126 TABLE 157 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 127 TABLE 158 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 127 TABLE 159 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 127 TABLE 160 BRAZIL: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 128 TABLE 161 BRAZIL: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 128 TABLE 162 BRAZIL: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 128 TABLE 163 BRAZIL: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 129 TABLE 164 BRAZIL: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 129 TABLE 165 BRAZIL: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 129 TABLE 166 MEXICO: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 130 TABLE 167 MEXICO: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 130 TABLE 168 MEXICO: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 130 TABLE 169 MEXICO: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 131 TABLE 170 MEXICO: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 131 TABLE 171 MEXICO: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 131 TABLE 172 ARGENTINA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 132 TABLE 173 ARGENTINA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 132 TABLE 174 ARGENTINA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 132 TABLE 175 ARGENTINA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 133 TABLE 176 ARGENTINA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 133 TABLE 177 ARGENTINA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 133 TABLE 178 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 134 TABLE 179 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 134 TABLE 180 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 134 TABLE 181 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 135 TABLE 182 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 135 TABLE 183 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 135 TABLE 184 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 137 TABLE 185 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 138 TABLE 186 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 138 TABLE 187 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 138 TABLE 188 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 139 TABLE 189 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 139 TABLE 190 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 139 TABLE 191 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 140 TABLE 192 GCC COUNTRIES: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 140 TABLE 193 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 141 TABLE 194 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 141 TABLE 195 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 141 TABLE 196 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 142 TABLE 197 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 142 TABLE 198 SOUTH AFRICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 142 TABLE 199 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 143 TABLE 200 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 143 TABLE 201 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 143 TABLE 202 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 144 TABLE 203 REST OF MEA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 144 TABLE 204 REST OF MEA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 144 TABLE 205 REST OF MEA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 145 TABLE 206 REST OF MEA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 145 TABLE 207 REST OF MEA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 145 TABLE 208 REST OF MEA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 146 TABLE 209 PUBLIC PLAYERS STOCK SUMMARY 150 TABLE 210 PRODUCT LAUNCH 151 TABLE 211 AMGEN INC.: PRODUCTS OFFERED 154 TABLE 212 AMGEN INC.: KEY DEVELOPMENTS 154 TABLE 213 PROCTER & GAMBLE: PRODUCTS OFFERED 158 TABLE 214 PROCTER & GAMBLE: KEY DEVELOPMENTS 158 TABLE 215 UNILEVER: PRODUCTS OFFERED 162 TABLE 216 PFIZER INC.: PRODUCTS OFFERED 166 TABLE 217 CIPLA: PRODUCTS OFFERED 169 TABLE 218 BAYER AG: PRODUCTS OFFERED 172 TABLE 219 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED 177 TABLE 220 GALDERMA: PRODUCTS OFFERED 180 TABLE 221 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED 183 TABLE 222 THORNTON & ROSS LTD.: PRODUCTS OFFERED 185 LIST OF FIGURES FIGURE 1 GLOBAL XEROSIS MARKET: STRUCTURE 23 FIGURE 2 GLOBAL XEROSIS TREATMENT: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 39 FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 42 FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 43 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL XEROSIS TREATMENT MARKET 45 FIGURE 6 GLOBAL XEROSIS TREATMENT MARKET, TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 52 FIGURE 7 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE, 2023 & 2032 (USD MILLION) 52 FIGURE 8 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY TYPE, 2023 53 FIGURE 9 GLOBAL XEROSIS TREATMENT MARKET, FORM SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 59 FIGURE 10 GLOBAL XEROSIS TREATMENT MARKET, BY FORM, 2023 & 2032 (USD MILLION) 59 FIGURE 11 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY FORM, 2023 60 FIGURE 12 GLOBAL XEROSIS TREATMENT MARKET, AGE GROUP SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 65 FIGURE 13 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP, 2023 & 2032 (USD MILLION) 65 FIGURE 14 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY AGE GROUP, 2023 66 FIGURE 15 GLOBAL XEROSIS TREATMENT MARKET, GENDER SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 69 FIGURE 16 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER, 2023 & 2032 (USD MILLION) 69 FIGURE 17 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY GENDER, 2023 70 FIGURE 18 GLOBAL XEROSIS TREATMENT MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 73 FIGURE 19 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION) 73 FIGURE 20 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023 74 FIGURE 21 GLOBAL XEROSIS TREATMENT MARKET, BY REGION, 2023 & 2032 (USD MILLION) 76 FIGURE 22 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY REGION, 2023 77 FIGURE 23 NORTH AMERICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 78 FIGURE 24 NORTH AMERICA XEROSIS TREATMENT MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 78 FIGURE 25 NORTH AMERICA XEROSIS TREATMENT MARKET SHARE (%), BY COUNTRY, 2023 79 FIGURE 26 EUROPE MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 86 FIGURE 27 EUROPE XEROSIS TREATMENT MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 86 FIGURE 28 EUROPE XEROSIS TREATMENT MARKET SHARE (%), BY COUNTRY, 2023 87 FIGURE 29 ASIA PACIFIC MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 104 FIGURE 30 ASIA PACIFIC: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 104 FIGURE 31 ASIA PACIFIC: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%) 105 FIGURE 32 SOUTH AMERICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 124 FIGURE 33 SOUTH AMERICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 125 FIGURE 34 SOUTH AMERICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%) 125 FIGURE 35 MIDDLE EAST AND AFRICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 136 FIGURE 36 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 137 FIGURE 37 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%) 137 FIGURE 38 GLOBAL XEROSIS TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 148 FIGURE 39 COMPETITOR DASHBOARD: GLOBAL XEROSIS TREATMENT MARKET 149 FIGURE 40 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 153 FIGURE 41 AMGEN INC.: SWOT ANALYSIS 154 FIGURE 42 PROCTER & GAMBLE: FINANCIAL OVERVIEW SNAPSHOT 157 FIGURE 43 PROCTER & GAMBLE: SWOT ANALYSIS 159 FIGURE 44 UNILEVER: FINANCIAL OVERVIEW SNAPSHOT 161 FIGURE 45 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 165 FIGURE 46 PFIZER INC.: SWOT ANALYSIS 166 FIGURE 47 CIPLA: FINANCIAL OVERVIEW SNAPSHOT 169 FIGURE 48 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 172 FIGURE 49 BAYER AG: SWOT ANALYSIS 173 FIGURE 50 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT 176 FIGURE 51 JOHNSON & JOHNSON INC.: SWOT ANALYSIS 178 FIGURE 52 GALDERMA: FINANCIAL OVERVIEW SNAPSHOT 180 FIGURE 53 DR. REDDY'S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 183

Single User Price	$4,950 USD
Multi User Licence (up to 10 users)	$5,950 USD
Enterprisewide Price (Global Site License)	$7,250 USD

授權報價

報告摘要

提及公司

同分類最新報告（醫療與生命科學）